首页|SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
The Omicron variant of SARS-CoV-2 evades antibody-mediated neutralization with unprecedented efficiency. At least three Omicron sublineages have been identified-BA.1, BA.2, and BA.3-and BA.2 exhibits increased transmissibility. However, it is currently unknown whether BA.2 differs from the other sublineages regarding cell entry and antibody-mediated inhibition. Here, we show that BA.1, BA.2, and BA.3 enter and fuse target cells with similar efficiency and in an ACE2-dependent manner. However, BA.2 was not efficiently neutralized by seven of eight antibodies used for COVID-19 therapy, including Sotrovimab, which robustly neutralized BA.1. In contrast, BA.2 and BA.3 (but not BA.1) were appreciably neutralized by Cilgavimab, which could constitute a treatment option. Finally, all sublineages were comparably and efficiently neutralized by antibodies induced by BNT162b2 booster vaccination after previous two-dose homologous or heterologous vaccination. Collectively, the Omicron sublineages show comparable cell entry and neutralization by vaccine-induced antibodies but differ in susceptibility to therapeutic antibodies.
Arora, Prerna、Zhang, Lu、Krueger, Nadine、Sidarovich, Anzhalika、Schulz, Sebastian、Kempf, Amy、Graichen, Luise、Moldenhauer, Anna-Sophie、Cossmann, Anne、Dopfer-Jablonka, Alexandra、Behrens, Georg M. N.、Jaeck, Hans-Martin、Poehlmann, Stefan、Hoffmann, Markus、Rocha, Cheila
NSTL
Elsevier
